Summary Neoplastic events are marked by uncontrolled cell proliferation. One major focus of cancer research has been to identify treatments that reduce or inhibit cell growth. Over the years, various compounds, both naturally occurring and chemically synthesized, have been used to inhibit neoplastic cell proliferation. Two such oncostatic agents, melatonin and retinoic acid, have been shown to suppress the growth of hormone-responsive breast cancer. Currently, separate clinical protocols exist for the administration of retinoids and melatonin as adjuvant therapies for cancer. Using the oestrogen receptor (ER)-positive MCF-7 human breast tumour cell line, our laboratory has studied the effects of a sequential treatment regimen of melatonin followed by all-trans retinoic acid (atRA) on breast tumour cell proliferation in vitro. Incubation of hormonally responsive MCF-7 and T47D cells with melatonin (10-9 M) followed 24 h later by atRA (10-9 M) resulted in the complete cessation of cell growth as well as a reduction in the number of cells to below the initial plating density. This cytocidal effect is in contrast to the growth-suppressive effects seen with either hormone alone. This regimen of melatonin followed by atRA induced cytocidal effects on MCF-7 cells by activating pathways leading to apoptosis (programmed cell death) as evidenced by decreased ER and Bcl-2 and increased Bax and transforming growth factor beta 1 (TGF-f1) expression. Apoptosis was reflected morphologically by an increase in the number of lysosomal bodies and perinuclear chromatin condensation, cytoplasmic blebbing and the presence of apoptotic bodies. The apoptotic effect of this sequential treatment with melatonin and atRA appears to be both cell and regimen specific as (a) ER-negative MDA-MB-231 and BT-20 breast tumour cells were unaffected, and (b) the simultaneous administration of melatonin and atRA was not associated with apoptosis in any of the breast cancer cell lines studied. Taken together, the results suggest that use of an appropriate regimen of melatonin and atRA should be considered for preclinical and clinical evaluation against ER-positive human breast cancer.
Melatonin, the major hormonal product of the pineal gland, has repeatedly been shown to exert a negative growth-regulatory influence on the development and growth of hormone-responsive breast cancer (Blask et al, 1986 (Blask et al, , 1991 . In addition, our laboratory (Hill and Blask, 1988) as well as others (Cos and Sanchez-Barcel6, 1994) have shown that melatonin treatment can act directly on hormoneresponsive human breast cancer cells in vitro to suppress their proliferation. We have also recently reported that melatonin not only suppresses the expression of the oestrogen receptor (ER) gene (Molis et al, 1994) , but also up-regulates steady-state mRNA levels of transforming growth factor beta (TGF-f) and the proto-oncogene, c-mync (Molis et al, 1995) . Even though the effects of melatonin on various growth-modulatory pathways have been observed, the exact mechanism by which melatonin suppresses breast tumour cell growth has not been conclusively identified. Two basic mechanisms have been proposed through which melatonin inhibits breast tumour cell growth. One mechanism is through a direct effect on breast tumour cells and the other through an indirect, neuroendocrine effect mediated via the hypothalamic-pituitary axis. Recent 1995). The second putative melatonin receptor consists of a group of nuclear receptors of the steroid hormone receptor superfamily that is closely associated with retinoic acid receptors. These putative melatonin receptors include the RZRa and RZRf (RORa) receptors (Becker-Andre et al, 1994; Steinhilber et al, 1995) .
Studies using human breast cancer cell lines indicate that retinoids inhibit the growth of ER-positive but not ER-negative cell lines (Lotan, 1979; Lacroix and Lippman, 1980; van der Burg et al, 1993) , with the exception of the ER-negative MDA-MB-157 cell line. Several growth-regulatory pathways are affected when breast tumour cell lines are exposed to retinoic acid (RA) (Lotan, 1979; Lacroix and Lippman, 1980; van der Burg et al, 1993) . For example, RA increases the activity of insulin-like growth factor binding protein one (IGF-BP-1), thereby reducing the mitogenic efficacy of IGF-1 in MCF-7 cells (Fontana et al, 1991) . In addition, treatment of ER-positive MCF-7 and T47D human breast cancer cells with RA induces secretion of growth-related proteins, including TGF-f (Fontana et al, 1990 ) and suppresses the expression of several key growth-regulatory proteins, including ER, progesterone receptor (PgR) and TGF-ox (Clarke et al, 1990; Rubin et al, 1994) . Differentiation and loss of her-2/neu expression may also be induced by RA (Bacus et al, 1990) . The effects of the retinoids, all-trans-RA (atRA) and 9-cis-RA (9cRA), are mediated by a 'M'CF-7 ' T47O.
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Figure (Giguere et al, 1987; Petkovich et al, 1987; Benbrook et al, 1988; Krust et al, 1989) . Hormonal treatment of breast cancer is frequently associated with cytostatic rather than cytocidal effects, and tumours often evolve under selective pressure to become resistant to endocrine therapy in breast cancer management (Miller, 1990) . The combinatory use of drugs with anti-oestrogenic effects might, thus, be an alternative to classical endocrine therapy. In this paper, we demonstrate that a sequential regimen of melatonin for 24 h followed by atRA results in decreased expression of ER and a significant induction of TGF-,B expression, and that the combined effect of melatonin and atRA induces apoptosis in hormone-responsive breast tumour cells.
MATERIALS AND METHODS Materials
Materials for cell culture and random priming kits were purchased from Gibco-BRL (Gaithersburg, MD, USA). 17-P Oestradiol, atRA and melatonin were purchased from Sigma (St Louis, MO, USA), and effector solutions were prepared in ethanol. RNAzol B reagent was purchased from Cinna-Biotex Laboratories (Houston, TX, USA), Hybond nylon transfer membrane was purchased from Amersham (Arlington Heights, IL, USA) and nitrocellulose membranes were purchased from Schleicher and Schuell (Keene, NH, USA Cell proliferation studies MCF-7 and MDA-MB-231 cells were plated at a density of 2 x 106 cells ml-' and BT-20 and T47D cells were plated at a density of 5 x 10-cells ml-' in 60-cm2 wells of six-well plates in IDMEM supplemented with 10% FBS. Five hours after seeding, the cells were treated with melatonin (10-9 M), atRA (109 M) or a combination of the two hormones. For timed regimens, the cells were treated with either melatonin or atRA for 24 h before the addition of the other hormone. The cells were grown, protected from light, in a humidified atmosphere in 5% CO2 at 37°C. On specific days (1, 3 or 5), triplicate wells were trypsinized, mixed with 2% trypan blue, and both total and viable cells were counted on a haemacytometer.
DNA extraction and electrophoresis
Total cellular DNA was isolated as previously described (Nicoletti et al, 1991) . Cells (1.5 x 107) were washed and resuspended in 0.5 ml of lysis buffer (50 mM Tris, 10 mM EDTA, 0.5% Triton X-100) with 5 mg ml' proteinase K and incubated at 37°C for 12 h. Lysates were then brought to a volume of 2.5 ml with lysis buffer and extracted twice with phenol-chloroform. DNA was precipitated, resuspended in 10 mM Tris (pH 8.0) with 0.1 mM EDTA and digested with 0.2 mg RNAase A for 2 h at 37°C. Approximately 20,tg of DNA from each sample was size fractionated on a 2% agarose gel, stained with ethidium bromide and photographed by UV transillumination to assess DNA oligomerization.
Transmission electron microscopy MCF-7 cells were cultured in IDMEM supplemented with 10%
FBS and plated at a density of 1 x 107 cells in a 75-cm2 flask. Cells were treated either with diluent (ethanol) or with melatonin (10-9 M) followed 24 h later by atRA (10-9 M). After 12, 24, 48 or 72 h of treatment, cells were harvested with a Ca2+-, Mg2+-free PBS/EDTA solution and pelleted by centrifugation (1000 g) for 5 min. Cell pellets were fixed in glutaraldehyde (3%) for 1.5 h and post-fixed with osmium tetroxide (2%) for 1 h in phosphate buffer (pH 7.3). The cells were then embedded in Epox. Ultra-thin (70 nm) sections were cut with a diamond knife, stained with 5% uranyl acetate and lead citrate, and were viewed with the JEOL CX II electron microscope at 60 kV. digested with Haelll. MCF-7 cells were treated for 1, 3 or 5 days with the sequential regimen of melatonin and atRA (M + R), after which high molecular weight DNA was isolated as described in Materials and methods.
DNA (20 igg) was run on a 2.0% agarose gel. This is a representative picture of three separate experiments Northern blot analysis of ER and TGF-p1 mRNA MCF-7 cells were seeded at a density of 3.0 x 106 cells per 150-cm2 flask in phenol red-free IDMEM supplemented with 5% CS-FBS. After 5 days in oestrogen-deficient medium, the cells were treated with either ethanol, melatonin (10-9 M), atRA (10-9 M) or a timed regimen of melatonin followed 24 h later by atRA. All treatments were continued for 24, 48 or 72 h. At the end of the treatment period, total RNA was isolated according to the method of Chomczynski and Sacchi (1987) using the RNAzol B reagent. Total RNA (50 jg) was separated electrophoretically on a 1% denaturing agarose gel containing 2.2 M formaldehyde and transferred to Hybond membranes by capillary action. The membranes were hybridized overnight with 32P-labelled ER, TGF-P, or 36B4 cDNA probes at 42°C. After high-stringency washes, filters were exposed to Kodak XOMAT-AR film with intensifying screens. Autoradiographs were scanned on the BioRad Imaging Densitometer GS-670 to determine the amount of ER and TGF-, 1 relative to 36B4 mRNA. Results were expressed as percentages of ER and TGF-4 1 mRNA levels in response to melatonin, atRA or the sequential regimen of melatonin and atRA compared with diluent controls.
Western blot analysis of Bcl-2 and Bax expression MCF-7 cells were treated with either diluent, melatonin, atRA or the sequential treatment of melatonin and atRA. Cultured cells were then washed twice with PBS and lysed in 300 p1 10-7 cells in 50 mM Tris (pH 8.0), 150 mm NaCl, 0. 1% sodium dodecyl sulphate (SDS), 0.5% sodium deoxycholate, 0.1% Triton X, 10 g ml' phenlymethylsulphonyl fluoride, 1 tg ml' aprotinin, I ,ug ml-' leupeptin and 0.02% sodium azide for 30 min at 4°C. Insoluble material was removed by centrifugation at 12 000 g for 15 min, and protein concentrations were determined using the BCA protein assay kit. The proteins (25 ,ug per lane) were size fractionated under denaturing conditions on 12.5% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Western blot analysis for Bcl-2 and Bax was conducted using rabbit polyclonal antibodies specific for the human Bcl-2 and Bax proteins as previously described (Krajewski et al, 1995) and an actin rabbit polyclonal antibody (Sigma) as a loading control. The proteins were visualized after incubation with horseradish peroxidase-conjugated secondary antibody (Sigma) and chemiluminescent substrate (Amersham), and exposure to Kodak XOMAT-AR film. Autoradiographs were scanned densitometrically to determine the amount of Bcl-2 and Bax proteins relative to the actin protein. Results were normalized to actin protein levels and are expressed as per cent of each day's individual control.
RESULTS
A sequential regimen of melatonin followed by atRA is cytocidal in ER-positive MCF-7 and T47D but not in ER-negative MDA-MB-231 or BT-20 human breast cancer cells
In light of recent reports that melatonin may be a ligand for the RORox receptors, that both melatonin and atRA can suppress the growth of ER-positive breast cancer cells (Lacroix and Lippman, 1980; Hill and Blask, 1988) and that the RORc and RARx receptors may crosstalk at the level of hormone response element, we initiated a series of studies to examine the possible additive or synergistic effects of melatonin and retinoic acid. As shown in Figure 1 A, ER-positive MCF-7 breast tumour cells showed significant growth suppression to 64% and 62% of control after 5 days of either melatonin (10-9 M) or atRA (10-9 M) treatment respectively. Surprisingly, the simultaneous treatment of cells with melatonin and atRA had no inhibitory effect on cell proliferation, and these cell numbers were equivalent to control values. However, a sequential regimen of melatonin (I0 9M) followed 24 h later by atRA (10-9 M) resulted in a cytocidal effect, decreasing cell numbers to below the initial plating density after 5 days of treatment. Sequential treatment with retinoic acid followed 24 h later by melatonin had a cytostatic effect in which cell proliferation was inhibited to 48% of control, but not a cytocidal effect. Similar results were seen with the ER-positive T47D cell line (Figure 1 B) in which melatonin and atRA, when used alone, inhibited cell proliferation to 60% and 61 % of control respectively; however, the simultaneous Effects of treatment with melatonin or atRA alone vs the sequential regimen of melatonin and atRA on steady-state ER and TGF-,1l mRNA levels in MCF-7 cells cultured in medium supplemented with 5% CS-FBS. MCF-7 cells were incubated with ethanol diluent (control), 10-9 M melatonin (Mel), 10-9 M atRA (atRA) or a regimen of melatonin followed 24 h later by atRA (M + R). For each time point, 50 ig of total RNA was fractionated on denaturing 1 % agarose gels and blotted as described in Materials and methods. Northern blots were probed with 32P-labeled human ER and human TGF-,B1 cDNAs. The 36B4 cDNA was used to monitor RNA loading. A representative autoradiograph is shown in (A). Autoradiographs from Northern blot analyses were quantified by scanning densitometry and normalized to 36B4 mRNA. Results are presented graphically in (B) as per cent of control (n = 3 independent experiments). *P < 0.001 vs controls, **P < 0.005 vs melatonin or atRA alone administration of melatonin and atRA also inhibited cell growth (54% vs control). T47D cells, like MCF-7 cells, showed a cytocidal response to the sequential regimen of melatonin and atRA. Sequential treatment with retinoic acid followed 24 h later by melatonin caused a cytostatic effect in which cell proliferation was inhibited to 39% of control, but a cytocidal effect was not observed. The specificity of the cytocidal effects is demonstrated by the fact that the sequential melatonin and atRA regimen had no effect on ER-negative MDA-MB-23 1 breast cancer cells ( Figure 1C ) nor on ER-negative BT-20 cells (data not shown).
Electrophoretic analysis of DNA isolated from MCF-7 cells treated at various times with the sequential regimen of melatonin and atRA The pattern of DNA oligomerization in MCF-7 tumour cells was determined at various times following the initiation of the sequential regimen of melatonin followed by atRA (Figure 2 ). Following treatment, the development, over time, of a ladder of nucleosomal oligomers was evident in MCF-7 cells. This laddering is characteristic of many cell types undergoing apoptosis. It should also be noted that there was no evidence of complete DNA degradation, which would be expected if the cells were undergoing cellular necrosis in response to treatment with melatonin followed by atRA.
Morphological changes in MCF-7 cells treated with the sequential regimen of melatonin and atRA Apoptosis is delineated from cellular necrosis by a unique series of ultrastructural changes, including chromosomal and cytoplasmic condensation, nuclear fragmentation, membrane blebbing, increased number of lysosomal bodies and the formation of membrane-bound apoptotic bodies. Following treatment with the sequential regimen of melatonin and atRA, MCF-7 cells were examined for ultrastructural changes indicative of necrosis or apoptosis. No distinctive morphological changes were noted in cells treated with the sequential regimen of melatonin and atRA until after 24 h of treatment, at which time an increase in lysosomal bodies, and perinuclear chromatin condensation was observed as compared with controls ( Figure 3A-C) . By 48 h, there was a further increase in the presence of lysosomal bodies and perinuclear chromatin condensation, and the cells had begun to demonstrate membrane blebbing ( Figure 3D ). After 72 h of treatment, membrane and cytoplasmic blebbing had increased and membrane-bound apoptotic bodies were evident. Based on the morphological criteria, it is evident that the treatment of MCF-7 cells with melatonin followed by atRA induced apoptosis rather than necrosis.
Effects of melatonin and atRA on the expression of the steady-state levels of ER and TGF-P mRNAs
The expression of the steady-state levels of mRNAs encoding the ER and TGF-31 was examined by Northern blot analysis in MCF-7 cells following 48 h of treatment with melatonin or atRA alone or with the sequential regimen of melatonin and atRA. For these studies, MCF-7 cells were grown for 5 days in oestrogen-deficient medium and treated with either melatonin or atRA alone (10-9 M) or pretreated with melatonin for 24 h before the addition of atRA. Figure 4A shows that both atRA and melatonin alone significantly decreased the steady-state level of ER mRNA by 62% and 79% Figure 5 The temporal effects of the sequential regimen of melatonin and atRA on steady-state TGF-,1 mRNA expression in MCF-7 cells. MCF-7 cells were cultured in medium supplemented with 5% CS-FBS. MCF-7 cells were incubated with diluent (ethanol), or a regimen of melatonin followed 24 h later by atRA for 1, 2 or 3 days. For each time point, 50 pg of total RNA was fractionated on denaturing 1% agarose gels and blotted as described in Materials and methods. Northern blots were probed with 32P-labeled human TGF-,B1 cDNAs. The 36B4 cDNA was used to monitor RNA loading. A representative autoradiograph is shown in (A). Autoradiographs from Northern blot analyses were quantified by scanning densitometry and normalized to 36B4 mRNA (n = 3 independent experiments). Results are presented graphically as per cent of control (B). *P < 0.001 vs controls, **P < 0.05 vs day 1 or 2 of treatment British Journal of Cancer (1998) 77(12), 2129-2137 3504 respectively (P < 0.01 vs control). However, the sequential regimen of melatonin and atRA reduced ER mRNA expression to almost undetectable levels (P < 0.001 vs melatonin or atRA alone). In addition, both atRA and melatonin alone enhanced the steady-state level of TGF-31 mRNA by 40% and 53% respectively, whereas the sequential regimen produced a super-induction of TGF-I mRNA levels (91% increase over control, and 65% and 52% increase over atRA or melatonin treatment respectively). Figure SA shows a representative Northern blot analysis of the time course of TGF-1 mRNA expression in response to the sequential treatment of MCF-7 cells with melatonin followed by atRA. By days I and 2 of treatment, TGF-1 mRNA levels were increased 30% and 70%, respectively, over controls ( Figure SB) .
By day 3, TGF-p1 mRNA was markedly elevated to approximately 200% over diluent controls. These results suggest that the sequential treatment of MCF-7 cells with melatonin followed by atRA results in a synergistic induction of TGF-f1 mRNA expression.
Temporal expression of Bcl-2 and Bax in MCF-7 cells in response to the timed treatment of melatonin and atRA
The relative levels of the Bcl-2 and Bax proteins were examined by Western blot analysis. Figure 6A and B shows representative Western blots of Bcl-2 and Bax expression 5 days after pretreatment with melatonin followed 24 h later by atRA. Densitometric analysis of these and other Western blots is shown in Figure 7 . The levels of Bcl-2 exhibited the greatest divergence from control levels on days 3 and 4, at which time Bcl-2 expression was reduced by 64% and 66% respectively as compared with control. Conversely, Bax expression appeared to decrease as compared with controls on day 4; however, this decrease was not statistically significant. On day 5, however, Bax expression was significantly increased over control by 58%. These results suggest that the sequential treatment regimen of melatonin followed by atRA suppresses the expression of the 'death suppresser', Bcl-2, on days 2, 3, 4 and 5 and enhances the expression of the 'death inducer', Bax, only on day 5.
DISCUSSION
Previous work by our laboratory (Hill and Blask, 1988) , as well as that of others (Cos and Sainchez-Barcelo, 1994) , has clearly demonstrated the growth-inhibitory effect of melatonin on human breast tumour cells. In addition, numerous laboratories have reported that both atRA and 9cRA are effective inhibitors of breast tumour cell proliferation (Lotan, 1979; Lacroix and Figure 6 The temporal effects of the sequential regimen of melatonin and atRA on Bcl-2 and Bax protein expression in MCF-7 cells. MCF-7 cells were incubated with diluent (control) or a regimen of melatonin followed 24 h later by atRA (M + atRA) for 1, 2, 3, 4 or 5 days. For each time point, 25 ,ug of total cellular protein per lane was fractionated on 12.5% polyacrylamide gels and transferred to nitrocellulose membranes as described in Materials and methods. Western blots were probed with polyclonal antibodies specific for Bcl-2 and Bax, and proteins were visualized after incubation with a horseradish peroxidaseconjugated secondary antibody and chemiluminescent substrate. Actin protein levels were used to monitor protein loading. Representative Western blots for Bcl-2 (A) and Bax (B) during 5 days of treatment with melatonin followed 24 h later by atRA are shown 1980; Fontana et al. 1990 Fontana et al. , 1991 van der Burg et al, 1993; Rubin et al, 1994) . Although each hormone has been shown to slow tumour proliferation, neither hormone alone has been shown to produce cytocidal effects in breast cancer cells at physiological concentrations. However, the results presented here show that, when used in a sequential manner (melatonin followed 24 h later by atRA), these hormones are able to act in an additive or synergistic manner to induce a cytocidal response and apoptosis in hormone-responsive breast tumour cells. For example, the formation of nucleosomal DNA oligomers, a phenomenon seen in many cells undergoing programmed cell death, was evident after treatment of MCF-7 cells with the timed regimen of melatonin and atRA. Furthermore, based on the morphological criteria of chromosomal condensation, nuclear fragmentation, membrane blebbing, increased number of lysosomal bodies and the formation of membrane-bound apoptotic bodies, it was clear that MCF-7 cells were undergoing apoptosis rather than necrosis in response to this treatment paradigm. The cytocidal effects produced by the sequential regimen of melatonin and atRA do not appear to result from non-specific cytotoxic effects, but, rather, are probably cell and treatment specific. This is evident by the lack of response of ERnegative (hormone-insensitive) MDA-MB-23 1 and BT-20 cells to the sequential regimen, and by the failure of the simultaneous administration of melatonin and atRA to induce apoptosis. (Ebisawa et al, 1994; Reppert et al, 1995) . Although controversial, some reports have also suggested that melatonin is able to bind and activate nuclear RORox receptors (Becker-Andre et al, 1994; Steinhilber et al, 1995 (Tini et al, 1995) . Expression of the 'death suppresser', Bcl-2 has previously been shown to be up-regulated by oestrogens in MCF-7 cells (Teixeira et al, 1995) , a process clearly mediated via the ER. The significant diminution of ER mRNA levels in response to the sequential regimen of melatonin and atRA raises the possibility that the down-regulation of Bcl-2 expression by this treatment is mediated indirectly via the reduction in ER expression. However, the lack of a 1:1 correlation between the per cent reduction in the levels of ER and Bcl-2 suggests that this treatment regimen may involve additional pathways that modulate Bcl-2 expression. Another potential contributor to these apoptotic effects could be the up-regulation of Bax protein seen on day 5 of the sequential treatment with melatonin and atRA. However, as Bax expression on day 4 appeared to decrease (not significantly) compared with controls, and as the increase in Bax expression observed on day 5 appeared much later than the onset of apoptosis in these cells, it is probable that this is a secondary effect rather than a primary contributor to the onset of apoptosis and must be interpreted with caution. It may be that the overall ratio of the 'death suppresser' (Bcl-2) to the 'death inducer' (Bax) is more important in mediating the apoptotic effects than is either one alone.
It is also possible that Bcl-2-and Bax-associated pathways play a secondary role, and that the overexpression of TGF-f1 induced by this sequential melatonin and atRA treatment is the critical event leading to apoptosis. TGF-f 1 has been shown to be a potent growth inhibitor of breast epithelium and breast tumour cells, particularly MICF-7 cells (Arteaga et al, 1990) . It is also known that oestrogen down-regulates TGF-131 expression and secretion in MCF-7 cells, and that the antioestrogen tamoxifen can block oestrogen's suppressive effect and promote enhanced TGF-I1 synthesis and secretion (Knabbe et al, 1987) . We have previously demonstrated that melatonin can up-regulate TGF-1 mRNA expression in a time course independent of the effects of oestrogen (Molis et al, 1995) . Thus, for the sequential treatment in which super-induction of TGF-1 expression occurs, two mechanisms are possible. First, the effects of this regimen may be mediated solely through the down-regulation of the oestrogen-response pathway and the secondary up-regulation of TGF-I1 levels. Alternatively, the effects on TGF-5l may be mediated by multiple pathways, including the oestrogen-response pathway. Studies are currently under way to determine if this sequential regimen of melatonin and atRA can induce apoptosis in the face of experimentally achieved reductions in TGF-j l levels.
Both melatonin and RA can inhibit the proliferation of various malignant cell types, including breast cancer. However, only retinoids have been shown to induce cell death and often when employed at supraphysiological concentrations (Lacroix and Lippman, 1980) . Thus, at least for RA, the major drawback to its use as a therapeutic agent is the toxicity induced at pharmacological doses. For this reason, the development of combinatorial therapies which would reduce the concentrations needed for clinical efficacy yet still enhance anti-tumorigenic activity would be of great benefit. Our data indicate that the antiproliferative effects of melatonin and RA on human breast cancer cells may be additive or synergistic when administered in the appropriate order, time and dose. In fact, when used in a given paradigm, they may be able to induce specifically apoptosis of breast tumour cells and the regression of breast tumours. This treatment regimen has been tested only in cultured breast cancer cells; therefore, the effects on primary human breast tumours or cell lines grown as xenografts may be very different from the effects observed in our long established MCF-7 breast cancer cell line. Our laboratory currently has studies in progress to investigate further the potential effects of our sequential treatment regimen on N-nitroso-Nmethylurea (NMU)-induced mammary tumours in the rat animal model. In order to define the optimal treatment parameters to induce tumour regression in vivo, a more detailed understanding of the biochemical pathway(s) involved in programmed cell death of breast tumour cells is needed. Tini M, Fraser RA and Gigiere V (1995) 
